STOK

Stoke Therapeutics, Inc. is a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with ribonucleic acid (RNA)-based medicines. The Company, through its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) approach, is engaged in developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its first compound, zorevunersen (STK-002), is in clinical testing for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy. TANGO aims to restore missing proteins by increasing or stoking protein output from healthy genes, thus compensating for the non-functioning copy of the gene. The Company is pursuing the development of STK-002 for the treatment of autosomal dominant optic atrophy (ADOA), the most common inherited optic nerve disorder. The Company’s initial focus is haploinsufficiency and diseases of the central nervous system and the eye.

Wall Street analysts forecast STOK stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for STOK is 31.75 USD with a low forecast of 25.00 USD and a high forecast of 39.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Stoke Therapeutics Inc revenue for the last quarter amounts to 10.63M USD, increased 117.25 % YoY.

Stoke Therapeutics Inc. EPS for the last quarter amounts to -0.65 USD, increased 38.30 % YoY.

Stoke Therapeutics Inc (STOK) has 128 emplpoyees as of December 15 2025.

Today STOK has the market capitalization of 1.85B USD.